Market Overview 2022-2027:
The global next-generation sequencing (NGS) market reached a value of US$ 13.82 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 40.25 Billion by 2027, exhibiting at a CAGR of 19.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Next-generation sequencing (NGS) is a parallel sequencing technology that determines the sequence of nucleotides in a section of the deoxyribonucleic acid (DNA). It involves various procedures, such as sequencing by synthesis (SBS) and ion semiconductor, single-molecule real-time (SMRT), and nanopore sequencing. It is a cost-effective solution that assists medical professionals in achieving precise results with high accuracy and speed. It also facilitates research in the fields of clinical diagnostics, personalized and genetic medicines, and agriculture and animal studies. At present, it is utilized in pharmacogenomics to escalate the drug delivery process.
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Next-Generation Sequencing (NGS) Market Trends:
The growing global geriatric population and the rising prevalence of various chronic medical disorders, such as cancer, cardiovascular, and neurological disorders, represent one of the key factors positively influencing the market. It can also be attributed to the growing use of genetic maps for guiding scientists to analyze the genes that are responsible for medical conditions. In addition, the widespread adoption of liquid biopsies in cancer diagnostics and the increasing utilization of NGS technologies to introduce non-invasive cancer biomarkers for real-time cancer monitoring and detection are creating a positive market outlook. In line with this, continuous technological innovations in sequencers, such as the integration of cloud-computing systems for enhanced data security and management, are strengthening the market growth. Apart from this, continuous financing by governments of various countries to improve healthcare infrastructure is providing a thrust to the market growth. Furthermore, increasing investments by leading players in research and development (R&D) activities for molecular biology, technical engineering, and sequencing chemistry is offering a favorable market outlook.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global next-generation sequencing (NGS) market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on sequencing type, product type, technology, application and end-user.
Breakup by Sequencing Type:
- Whole Genome Sequencing
- Targeted Resequencing
- Whole Exome Sequencing
- RNA Sequencing
- CHIP Sequencing
- De Novo Sequencing
- Methyl Sequencing
- Others
Targeted resequencing represents the largest market segment due to the presence of numerous companies in the NGS market offering targeted resequencing services.
Breakup by Product Type:
- Instruments
- Reagents and Consumables
- Software and Services
Reagents and consumables represent the most commonly used product type that assists in sample preparation, DNA isolation, sample cleanup, target enrichment, and quality assurance.
Breakup by Technology:
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Sequencing by Synthesis
- Ion Semiconductor Sequencing
- Single-Molecule Real-Time Sequencing
- Nanopore Sequencing
- Others
Sequencing by synthesis finds extensive applications on account of its high accuracy in performing DNA sequencing and its growing incorporation in NGS instrumentation. In addition, it offers the highest yield of error-free throughput results.
Breakup by Application:
- Biomarker and Cancer
- Drug Discovery and Personalized Medicine
- Genetic Screening
- Diagnostics
- Agriculture and Animal Research
- Others
Biomarker and cancer currently dominate the market due to the rising prevalence of cancer and increasing awareness among individuals about the benefits of early diagnosis and treatment.
Breakup by End-User:
- Academic Institutes & Research Centers
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Others
Academic institutes and research centers account for the majority of the market share due to the increasing application of NGS solutions in research projects.
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
North America exhibits a clear dominance in the market due to the availability of a technologically advanced healthcare research framework in the region, coupled with the presence of multiple clinical laboratories that employ NGS to provide genetic testing services.
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V., GenapSys Inc., etc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Billion |
Segment Coverage |
Sequencing Type, Product Type, Technology, Application, End-User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V. and GenapSys Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |